Molina J M, Córdoba J, Gil A, Gobernado M
Servicio de Microbiologiá, Hospital La Fe, Valencia.
Rev Esp Quimioter. 2007 Sep;20(3):346-53.
HIV resistance to antiretroviral drugs was studied in 348 samples taken from patients at the Molecular Biology Unit of the Microbiology Department of the Hospital La Fe, from January 2003 to July 2007. Once the viral load in plasma was determined, resistance was detected using complete gene sequencing for protease up to position 3464 of the HIV-1 reverse transcriptase gene. The results were analyzed using the Omiga 1.2 (Oxford Molecular Group) and HIV db Genotypic Resistance Interpretation Algorithm Version 4.3.0 (Stanford University) programs. The drugs least affected by the presence of mutations leading to resistance were the protease inhibitors darunavir, tripanavir and lopinavir (sensitivity >80%), the nucleoside reverse transcriptase inhibitors tenofovir and lamivudine (sensitivity >90%) and the non-nucleoside reverse transcriptase inhibitor TMC125 (sensitivity >80%).
2003年1月至2007年7月期间，在拉费医院微生物学系分子生物学单元从患者身上采集的348份样本中，研究了HIV对抗逆转录病毒药物的耐药性。一旦确定血浆中的病毒载量，就使用HIV-1逆转录酶基因第3464位之前的蛋白酶完整基因测序来检测耐药性。使用Omiga 1.2（牛津分子集团）和HIV数据库基因型耐药性解读算法版本4.3.0（斯坦福大学）程序对结果进行分析。受导致耐药性的突变影响最小的药物是蛋白酶抑制剂地瑞那韦、替拉那韦和洛匹那韦（敏感性>80%）、核苷类逆转录酶抑制剂替诺福韦和拉米夫定（敏感性>90%）以及非核苷类逆转录酶抑制剂TMC125（敏感性>80%）。
